Literature DB >> 28585912

Anti-HLA Antibodies Testing on Solid Phase: Comparative Evaluation of Different Kit Vendors Through Luminex Technology.

Pellegrino Biagio Minucci1, Marianna Resse, Chiara Sabia, Antonella Esposito, Gustavo De Iorio, Claudio Napoli.   

Abstract

OBJECTIVES: For decades, the detection of anti-HLA antibodies in candidates for solid-organ transplant has been performed with the traditional complement-dependent cytotoxicity method; this assay has been then integrated with the introduction of solid-phase assays. Over the past 20 years, the Luminex assay has become the most widely used in clinical laboratories due to both increased sensitivity and specificity versus enzyme-linked immunosorbent assay. However, even the Luminex technique has shown some critical issues, and choosing the most reliable method still remains challenging. In this study, we verified the concordance of the results obtained in detecting anti-HLA antibodies with 2 kit vendors that provide reagents for the Luminex platform.
MATERIALS AND METHODS: We used 314 serum samples from patients on wait lists for solid-organ transplant. Sera were tested with LABScreen Mixed-LSM12 (One Lambda-Thermo Fisher, Canoga Park, CA, USA) and LIFECODES LifeScreen Deluxe-LMX (Gen-Probe-Immucor, Stanford, CT, USA),which we indicated as vendor A and vendor B, respectively. Anti-HLA class I and class II antibody analyses were conducted by verifying the concordance of the results with Cohen kappa coefficient statistics and confidence interval.
RESULTS: The kappa coefficient statistics showed "substantial" reliability for class I (0.61; confidence interval, 0.50-0.73) and "moderate" reliability for class II (0.56; confidence interval, 0.43-0.69). There were no considerable differences in results between the 2 kits regarding overall assignment of negativity or positivity of a sample. Discordant data between positive values for a test and negative for the other were found for samples with weak antibody positivity.
CONCLUSIONS: Some discordant data were probably attributable to several factors such as the composition of the kits, the antibody titer in the serum, whether sera were diluted, different washing methods, and type of plate used.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28585912     DOI: 10.6002/ect.2016.0199

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  3 in total

1.  Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study.

Authors:  Antoine Roux; Kimberly A Thomas; Edouard Sage; Caroline Suberbielle-Boissel; Laurence Beaumont-Azuar; Francois Parquin; Morgan Le Guen; Nicholas Harre; Abdul Monem Hamid; Elaine F Reed
Journal:  Transpl Int       Date:  2018-04-22       Impact factor: 3.782

2.  Biomarker profile in stable Fontan patients.

Authors:  Anita Saraf; Christine De Staercke; Ian Everitt; Alice Haouzi; Yi-An Ko; Staci Jennings; Jonathan H Kim; Fred H Rodriguez; Andreas P Kalogeropoulos; Arshed Quyyumi; Wendy Book
Journal:  Int J Cardiol       Date:  2020-01-09       Impact factor: 4.164

3.  Low incidence of IgA isotype of HLA antibodies in alloantigen exposed individuals.

Authors:  Helena Car; Gonca E Karahan; Geertje J Dreyer; Simone H Brand-Schaaf; Aiko P J de Vries; Cees van Kooten; Cynthia S M Kramer; Dave L Roelen; Frans H J Claas; Sebastiaan Heidt
Journal:  HLA       Date:  2020-12-02       Impact factor: 4.513

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.